Literature DB >> 12923729

Therapy of membranous nephropathy associated with malignancy and secondary causes.

J Ashley Jefferson1, William G Couser.   

Abstract

Membranous nephropathy (MN) most commonly is idiopathic, but secondary causes are common in children and in older adults. The most common secondary causes of MN in industrialized countries include malignancy and systemic lupus erythematosis. Infectious causes (hepatitis B, quartan malaria, schistosomiasis) remain the most common etiologies in endemic areas. In this article we describe the clinical approach to patients with MN associated with malignancy and other common secondary causes. Treatment of secondary MN generally targets the primary disease rather than the renal lesion.

Entities:  

Mesh:

Year:  2003        PMID: 12923729     DOI: 10.1016/s0270-9295(03)00055-x

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  19 in total

1.  Experimental Models of Membranous Nephropathy.

Authors:  J Ashley Jefferson; Jeffrey W Pippin; Stuart J Shankland
Journal:  Drug Discov Today Dis Models       Date:  2010

2.  A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma.

Authors:  Tomohiro Kaneko; Akira Shimizu; Michiko Aoki; Shuichi Tsuruoka
Journal:  CEN Case Rep       Date:  2014-07-18

3.  Antimalarial Drugs for the Prevention of Chronic Kidney Disease in Patients with Rheumatoid Arthritis: The Importance of Controlling Chronic Inflammation?

Authors:  Jennifer C Rodrigues; Joanne M Bargman
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-16       Impact factor: 8.237

4.  Clinical improvement of membranous nephropathy after endoscopic resection of double early gastrointestinal cancers.

Authors:  Satoshi Matsui; Hiroko Tsuji; Yukinobu Takimoto; Shinji Ono
Journal:  Clin Exp Nephrol       Date:  2010-12-16       Impact factor: 2.801

Review 5.  Membranous nephropathy in the older adult: epidemiology, diagnosis and management.

Authors:  Jeroen K J Deegens; Jack F M Wetzels
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

6.  Nephrotic syndrome as a clinical manifestation of systemic sclerosis.

Authors:  Ewa Wielosz; Maria Majdan; Dorota Suszek; Iwona Smarz-Widelska; Agnieszka Korolczuk; Elzbieta Korobowicz
Journal:  Rheumatol Int       Date:  2007-04-11       Impact factor: 2.631

7.  Membranous nephropathy in an HIV-positive patient complicated with hepatitis B virus infection.

Authors:  Akihiko Numata; Tetsu Akimoto; Masaki Toshima; Yoshitaka Iwazu; Naoko Otani; Takuya Miki; Taro Sugase; Osamu Saito; Yoshitomo Hamano; Fumi Takemoto; Yoshihiko Ueda; Shigeaki Muto; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2011-06-29       Impact factor: 2.617

8.  Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis.

Authors:  Huanzi Dai; Huhai Zhang; Yani He
Journal:  Sci Rep       Date:  2015-03-05       Impact factor: 4.379

9.  Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains.

Authors:  In O Sun; Yu Ah Hong; Hoon Suk Park; Sun Ryoung Choi; Byung Ha Chung; Cheol Whee Park; Chul Woo Yang; Yong Soo Kim; Bum Soon Choi
Journal:  Korean J Intern Med       Date:  2012-11-27       Impact factor: 2.884

10.  Membranous glomerulonephritis associated with Mycobacterium shimoidei pulmonary infection.

Authors:  Nobuhiro Kanaji; Yoshio Kushida; Shuji Bandoh; Tomoya Ishii; Reiji Haba; Akira Tadokoro; Naoki Watanabe; Takayuki Takahama; Nobuyuki Kita; Hiroaki Dobashi; Takuya Matsunaga
Journal:  Am J Case Rep       Date:  2013-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.